Data gathered: December 26
AI Stock Analysis - Biomea Fusion (BMEA)
Analysis generated June 22, 2024. Powered by Chat GPT.
Biomea Fusion is a cutting-edge biopharmaceutical company dedicated to the discovery and development of novel small-molecule covalent medicines. The company's innovative platform is designed to treat various diseases, emphasizing oncology and metabolic disorders. Biomea Fusion's commitment to research and development positions them as a unique player in the biopharmaceutical sector, leveraging next-generation covalent bonding techniques to create groundbreaking treatments.
Stock Alerts - Biomea Fusion (BMEA)
 |
Biomea Fusion | December 26 Twitter followers are up by 8.5% in the last 24h. |
|
Biomea Fusion | December 25 Twitter followers are up by 7% in the last 24h. |
|
Biomea Fusion | December 23 Twitter followers are up by 5% in the last 24h. |
|
Biomea Fusion | December 20 Twitter followers are down by 2.5% in the last 24h. |
Alternative Data for Biomea Fusion
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | 4 | Sign up | Sign up | Sign up |
| Sentiment | 84 | Sign up | Sign up | Sign up |
| Webpage traffic | 6,000 | Sign up | Sign up | Sign up |
| Employee Rating | 60 | Sign up | Sign up | Sign up |
| Google Trends | 20 | Sign up | Sign up | Sign up |
| Patents | 11 | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Facebook Engagement | N/A | Sign up | Sign up | Sign up |
| Facebook Followers | 173 | Sign up | Sign up | Sign up |
| Instagram Followers | 4,809 | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 6 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 1,442 | Sign up | Sign up | Sign up |
| Twitter Followers | 7,968 | Sign up | Sign up | Sign up |
| Twitter Mentions | 20 | Sign up | Sign up | Sign up |
| Youtube Subscribers | 130 | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| Business Outlook | 64 | Sign up | Sign up | Sign up |
| Linkedin Employees | 99 | Sign up | Sign up | Sign up |
About Biomea Fusion
Biomea Fusion, Inc., a biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases.
| Price | $4.10 |
| Target Price | Sign up |
| Volume | 101,870 |
| Market Cap | $145M |
| Year Range | $3.88 - $13.24 |
| Dividend Yield | 0% |
| Analyst Rating | 82% buy |
| Industry | Biotechnology |
In the news
 |
Biomea Fusion Announces Positive Topline Results from COVALENT-111 Clinical TrialDecember 22 - ETF Daily News |
Biomea Fusion : Announces Positive Topline Results from Ongoing Phase II COVALENT 111 Study in Patients with Type 2 Diabetes Form 8 KDecember 19 - Finnhub |
|
|
Analysts Set Biomea Fusion, Inc. (NASDAQ:BMEA) Target Price at $39.36December 19 - ETF Daily News |
|
HC Wainwright Reiterates “Buy” Rating for Biomea Fusion (NASDAQ:BMEA)December 17 - ETF Daily News |
Why Is Diabetes-Drug Developer Biomea Fusion Stock Trading Lower On Tuesday?December 17 - Yahoo Entertainment |
|
Biomea Fusion Announces Positive Topline Results from Ongoing Phase II COVALENT-111 Study in Patients with Type 2 DiabetesDecember 17 - GlobeNewswire |
|
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q3 '24 | 0 | 6.8M | -6.8M | -33M | -34M | -0.910 |
| Q2 '24 | 0 | 7.1M | -7.1M | -37M | -38M | -1.030 |
| Q1 '24 | 0 | 7.3M | -7.3M | -39M | -41M | -1.090 |
| Q4 '23 | 6.1M | 6.5M | -6.5M | -35M | -36M | -0.980 |
| Q3 '23 | 0 | 5.8M | -5.8M | -28M | -31M | -0.800 |
Insider Transactions View All
| Hitchcock Michael J.M. filed to buy 15,000 shares at $10.1. October 1 '24 |
| Valle Franco filed to buy 42,500 shares at $4.4. June 12 '24 |
| A2A Pharmaceuticals, Inc. filed to sell 3,500,000 shares at $34.6. June 2 '23 |
| A2A Pharmaceuticals, Inc. filed to sell 3,550,000 shares at $33.8. June 2 '23 |
| A2A Pharmaceuticals, Inc. filed to sell 3,625,000 shares at $33.8. May 17 '23 |
Similar companies
Read more about Biomea Fusion (BMEA) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, employee rating, google trends, patents, 4chan mentions, facebook engagement, facebook followers, instagram followers, reddit mentions, stocktwits mentions, stocktwits subscribers, twitter followers, twitter mentions, youtube subscribers, news mentions, customer reviews, business outlook & linkedin employees.
What is the Market Cap of Biomea Fusion?
The Market Cap of Biomea Fusion is $145M.
What is the current stock price of Biomea Fusion?
Currently, the price of one share of Biomea Fusion stock is $4.10.
How can I analyze the BMEA stock price chart for investment decisions?
The BMEA stock price chart above provides a comprehensive visual representation of Biomea Fusion's stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Biomea Fusion shares. Our platform offers an up-to-date BMEA stock price chart, along with technical data analysis and alternative data insights.
Does BMEA offer dividends to its shareholders?
As of our latest update, Biomea Fusion (BMEA) does not offer dividends to its shareholders. Investors interested in Biomea Fusion should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
What are some of the similar stocks of Biomea Fusion?
Some of the similar stocks of Biomea Fusion are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
.